MetaCap

Recursion Pharmaceuticals (RXRX) vs Windward Bio Group (WWB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Recursion Pharmaceuticals is the larger company by market cap ($1.53 billion vs $1.45 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RXRX-23.08%WWB-14.79%
+7%-9%-25%
Nov 13, 20261 yearNov 20, 2026
RXRX-23.08%WWB-14.79%
+1%-12%-24%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RXRX versus WWB key metrics
MetricRXRXWWB
Share price$2.45$24.29
Market cap$1.53B$1.45B
1-day change-9.93%+1.15%
YTD return-40.10%—
1-year return-41.25%—
5-year return-87.04%—
EPS (TTM)$-0.86$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$74.68M—
Revenue growth (YoY)+26.92%—
Net income (latest FY)$-644.76M—
Gross margin4.99%—
Operating margin-867.87%—
Net margin-863.35%—
52-week high$5.24$33.99
52-week low$2.44$18.35
Distance from 52-week high-53.24%-28.55%
Analyst consensusbuy—
Avg. price target upside+176.33%—
Average volume24.47M434.33K
Shares outstanding622.76M59.58M
Employees60033
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Recursion Pharmaceuticals

RXRX stock →

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees

About Windward Bio Group

WWB stock →

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees

RXRX vs WWB FAQ

Which is bigger, Recursion Pharmaceuticals or Windward Bio Group?

Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $1.53B compared with $1.45B for Windward Bio Group (WWB).

Are Recursion Pharmaceuticals and Windward Bio Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons